STERIS plc

NYSE:STE Rapport sur les actions

Capitalisation boursière : US$20.0b

STERIS Croissance future

Future contrôle des critères 1/6

STERIS devrait augmenter ses bénéfices et son chiffre d'affaires de 10.2% et de 6% par an respectivement. Le BPA devrait croître de de 10.7% par an. Le rendement des capitaux propres devrait être 13.8% dans 3 ans.

Informations clés

10.2%

Taux de croissance des bénéfices

10.72%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices16.9%
Taux de croissance des recettes6.0%
Rendement futur des capitaux propres13.79%
Couverture par les analystes

Good

Dernière mise à jour11 Sep 2026

Mises à jour récentes de la croissance future

Recent updates

Mise à jour du récit • Aug 09

STE: North Carolina Expansion And Dividend Growth Will Support Future Upside

Analysts have modestly raised their price target for STERIS to about $262 per share. This reflects updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E.
Seeking Alpha • Jul 27

Steris: A Good Moment To Buy Shares In This Sterilization Leader

Summary Steris provides infection prevention products and sterilization services to medical clientele (such as hospitals, outpatient surgery centers, and pharmaceutical companies). Steris has increased its dividend for 21 consecutive years. The 10-year dividend growth rate of 9.6% is strong, but more recent dividend raises have actually been over 10%. STE has a great financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is over 18. The P/E ratio is now down to 26.6. That’s far lower than its five-year average of 46.8. Read the full article on Seeking Alpha
Mise à jour du récit • Jun 24

STE: Share Repurchases And Recurring Platform Earnings Will Support Future Upside

Analysts have made a small adjustment to their price target on STERIS, keeping fair value around $256.86 while fine-tuning assumptions on discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News STERIS reported fiscal 2026 adjusted EPS of $10.17 compared with $9.22 a year earlier and total revenue of $5.94b, with broad-based revenue growth led by healthcare and faster percentage gains in Life Sciences.
Mise à jour du récit • Jun 04

STE: Share Repurchases And Earnings Outlook Will Support Future Upside

Analysts have trimmed their price target for STERIS to $256.86 from $279.29, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that collectively point to a lower fair value estimate. What's in the News STERIS announced a share repurchase program authorizing the company to buy back up to US$1,000 million of its ordinary shares.
Mise à jour du récit • May 11

STE: Lower Discount Rate And Stable Assumptions Will Support Future Upside

Analysts have maintained their $279.29 price target for STERIS, supported by a slightly lower discount rate and minor adjustments to long-term revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: Maintained at $279.29 per share, with no change in the updated analysis.
Mise à jour du récit • Apr 26

STE: Share Repurchases And Stable Assumptions Will Support Future Upside

Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).
Mise à jour du récit • Apr 11

STE: Completed Buyback And Stable Assumptions Will Support Future Upside

Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.
Mise à jour du récit • Mar 28

STE: Completed Buyback And Refined Assumptions Will Support Future Upside

Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.
Article d’analyse • Mar 24

Is There Now An Opportunity In STERIS plc (NYSE:STE)?

STERIS plc ( NYSE:STE ) received a lot of attention from a substantial price movement on the NYSE over the last few...
Mise à jour du récit • Mar 11

STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside

Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.
Mise à jour du récit • Feb 25

STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside

Analysts have slightly trimmed their fair value estimate for STERIS to about $281 from roughly $282, reflecting modest tweaks to assumptions on the discount rate, long term revenue growth, profit margin, and future P/E expectations. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares.
Mise à jour du récit • Feb 10

STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View

Analysts have slightly adjusted their price target for STERIS to US$281.63, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors suggest a modest recalibration of expectations rather than a major shift in outlook.
Mise à jour du récit • Jan 27

STE: Share Repurchases And Stable Outlook Will Support A Fair View

Analysts have kept their fair value estimate for STERIS steady at about $281.63 per share, while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the company’s long term earnings power. What's in the News From July 1, 2025 to September 30, 2025, STERIS repurchased 400,000 shares, representing 0.41% of its shares, for $98.64 million under its existing buyback program (Key Developments).
Mise à jour du récit • Jan 10

STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook

Analysts have kept their fair value estimate for STERIS essentially unchanged at about US$281.63, citing only very small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that do not materially affect their overall price target view. What's in the News STERIS repurchased 400,000 shares from July 1, 2025 to September 30, 2025, representing 0.41% of shares for US$98.64 million, as part of its ongoing buyback program.
Article d’analyse • Jan 09

Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Article d’analyse • Dec 26

Earnings Tell The Story For STERIS plc (NYSE:STE)

With a price-to-earnings (or "P/E") ratio of 36.4x STERIS plc ( NYSE:STE ) may be sending very bearish signals at the...
Mise à jour du récit • Dec 23

STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook

Analysts have modestly raised their price target on STERIS to $281.63, reflecting slightly higher long term growth and profitability expectations, despite largely unchanged model assumptions. What's in the News STERIS completed a share repurchase tranche between July 1 and September 30, 2025, buying back 400,000 shares, or 0.41% of shares outstanding, for $98.64 million (Key Developments).
Mise à jour du récit • Dec 09

STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook

Analysts have modestly raised their price target on STERIS to approximately $282 per share from about $281.60, reflecting slightly lower perceived risk and a steady outlook for revenue growth, profit margins, and long term valuation multiples. What's in the News Completed a share repurchase program totaling 1,307,158 shares, or about 1.32% of shares outstanding, for $298.64 million under the buyback announced on May 3, 2023 (company filing).
Mise à jour du récit • Nov 25

STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance

Analysts have raised their price target for STERIS from $278.38 to $281.63. This change reflects modest expectations for improved revenue growth, even though there have been minor adjustments to other key financial metrics.
Mise à jour du récit • Nov 07

STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value

Analysts have raised their price target for STERIS from $272.38 to $278.38. They cite marginal improvements in projected profit margins, even though revenue growth expectations have been slightly reduced.
Article d’analyse • Oct 27

Is STERIS (NYSE:STE) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Mise à jour du récit • Sep 05

Healthcare Demand And Facility Expansion Will Create Value

With STERIS’s discount rate and future P/E both virtually unchanged, analyst valuation perspectives remain steady, resulting in an unchanged consensus price target of $272.38. What's in the News STERIS completed $200 million in share repurchases, totaling 907,158 shares (0.92%) under its current buyback program; no additional shares were repurchased in the latest quarter.
Seeking Alpha • Mar 22

Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'

Summary Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments. Key risks include weak capital equipment sales due to economic conditions, but overall, Steris's differentiated AST portfolio supports a positive long-term outlook. Read the full article on Seeking Alpha
Seeking Alpha • Nov 18

Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'

Summary I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business. Key risks include potential legal liabilities from EtO emissions and weak near-term growth in healthcare capital equipment revenue. Read the full article on Seeking Alpha

Prévisions de croissance des bénéfices et des revenus

NYSE:STE - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
3/31/20297,2071,173N/AN/A4
3/31/20286,7781,019N/A1,4419
3/31/20276,372889N/A1,3049
6/30/20266,0388059261,289N/A
3/31/20265,9367829721,341N/A
12/31/20255,8287099171,267N/A
9/30/20255,7036899611,301N/A
6/30/20255,5716489091,264N/A
3/31/20255,4606107781,148N/A
12/31/20245,3986177511,142N/A
9/30/20245,3265916801,101N/A
6/30/20245,235561594996N/A
3/31/20245,139551613973N/A
12/31/20234,6831,036594934N/A
9/30/20234,6011,012535849N/A
6/30/20234,563576494806N/A
3/31/20234,536557395757N/A
12/31/20224,784-28349713N/A
9/30/20224,777-8399752N/A
6/30/20224,773377472819N/A
3/31/20224,223285397685N/A
12/31/20214,248279412701N/A
9/30/20213,848250400662N/A
6/30/20213,407286424653N/A
3/31/20213,108397450690N/A
12/31/20203,057433476701N/A
9/30/20203,022424400627N/A
6/30/20203,003413384615N/A
3/31/20203,031408N/A591N/A
12/31/20192,976393N/A570N/A
9/30/20192,898336N/A573N/A
6/30/20192,840319N/A548N/A
3/31/20192,782304N/A540N/A
12/31/20182,730269N/A490N/A
9/30/20182,696316N/A467N/A
6/30/20182,651303N/A478N/A
3/31/20182,620291N/A458N/A
12/31/20172,585243N/A463N/A
9/30/20172,570144N/A453N/A
6/30/20172,582120N/A424N/A
3/31/20172,613110N/A424N/A
12/31/20162,616142N/A439N/A
9/30/20162,588167N/A364N/A
6/30/20162,431135N/A294N/A
3/31/20162,233111N/A255N/A
12/31/20152,04294N/A185N/A
9/30/20151,897113N/A221N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de STE ( 10.2% par an) est supérieure au taux d'épargne ( 3.7% ).

Bénéfices vs marché: Les bénéfices de STE ( 10.2% par an) devraient croître plus lentement que le marché US ( 17.5% par an).

Croissance élevée des bénéfices: Les bénéfices de STE devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de STE ( 6% par an) devrait croître plus lentement que le marché de US ( 13.6% par an).

Croissance élevée des revenus: Le chiffre d'affaires de STE ( 6% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de STE devrait être faible dans 3 ans ( 13.8 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/09/21 11:10
Cours de l'action en fin de journée2026/09/21 00:00
Les revenus2026/06/30
Revenus annuels2026/03/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

STERIS plc est couverte par 17 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Michael PolarkBaird
Erin Wilson WrightBofA Global Research
David TurkalyCitizens JMP Securities, LLC